Spero Therapeutics (NASDAQ:SPRO) Issues Earnings Results

Spero Therapeutics (NASDAQ:SPRO) announced its quarterly earnings data on Thursday. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03), Zacks reports. The company had revenue of $15.04 million for the quarter, compared to analyst estimates of $12.40 million. Spero Therapeutics had a return on equity of 4.03% and a net margin of 3.30%.

Spero Therapeutics Stock Performance

NASDAQ SPRO opened at $0.77 on Friday. Spero Therapeutics has a one year low of $0.73 and a one year high of $1.81. The company has a 50-day simple moving average of $0.82 and a 200-day simple moving average of $1.05. The firm has a market capitalization of $41.98 million, a PE ratio of 11.00 and a beta of 0.68.

Insider Buying and Selling

In other news, Director Ankit Mahadevia sold 69,219 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total transaction of $53,990.82. Following the completion of the transaction, the director now owns 689,866 shares of the company’s stock, valued at approximately $538,095.48. The trade was a 9.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Sath Shukla sold 155,333 shares of the company’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total transaction of $121,159.74. Following the transaction, the chief executive officer now owns 1,736,883 shares of the company’s stock, valued at $1,354,768.74. This represents a 8.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 245,241 shares of company stock worth $191,288 over the last quarter. 4.52% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Spero Therapeutics in a research report on Thursday, January 30th. Evercore ISI downgraded Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price on the stock. in a report on Friday, December 20th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.